Immuron Ltd
IMRNDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 27, 2026
9dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
IMRN Earnings Report
FQ end 2026-06
IMM-124E
Non-alcoholic Steatohepatitis (NASH)
Travelan
Diarrhea
IMM 124-E (Hyperimmune Bovine Colostrum)
Hepatitis, Alcoholic
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
IMM-124E | Phase 2 | Non-alcoholic Steatohepatitis (NASH) | - | - |
Travelan | Phase 2 | Diarrhea | - | - |
IMM 124-E (Hyperimmune Bovine Colostrum) | Phase 2 | Hepatitis, Alcoholic | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Immuron Ltd's drug pipeline?→
CatalystAlert tracks 3 drug candidates in Immuron Ltd's (IMRN) pipeline across Phase 2. Its lead program is IMM-124E (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Immuron Ltd's next FDA catalyst?→
Immuron Ltd's (IMRN) next tracked catalyst is a Earnings expected August 27, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IMRN biotech catalysts?→
Add IMRN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Immuron Ltd's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.